These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 35941422)

  • 21. Acute, long-term or non-vincristine-induced peripheral neuropathy among non-Hodgkin lymphoma survivors: Symptoms, daily activities, functional status, and quality of life.
    Su YC; Lai YH; Hsieh ST; Teng CJ; Lee YH
    Eur J Oncol Nurs; 2024 Apr; 69():102540. PubMed ID: 38461728
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Incidence, description, predictors, and consequences of persistent taxane-induced peripheral neuropathy.
    Hertz DL
    Curr Opin Support Palliat Care; 2024 Mar; 18(1):30-38. PubMed ID: 38126251
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evaluating the impact of chemotherapy-induced peripheral neuropathy symptoms (CIPN-sx) on perceived ability to work in breast cancer survivors during the first year post-treatment.
    Zanville NR; Nudelman KN; Smith DJ; Von Ah D; McDonald BC; Champion VL; Saykin AJ
    Support Care Cancer; 2016 Nov; 24(11):4779-89. PubMed ID: 27470258
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Gait, balance, and patient-reported outcomes during taxane-based chemotherapy in early-stage breast cancer patients.
    Monfort SM; Pan X; Patrick R; Ramaswamy B; Wesolowski R; Naughton MJ; Loprinzi CL; Chaudhari AMW; Lustberg MB
    Breast Cancer Res Treat; 2017 Jul; 164(1):69-77. PubMed ID: 28374323
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Chemotherapy-induced peripheral neuropathy, physical activity and health-related quality of life among colorectal cancer survivors from the PROFILES registry.
    Mols F; Beijers AJ; Vreugdenhil G; Verhulst A; Schep G; Husson O
    J Cancer Surviv; 2015 Sep; 9(3):512-22. PubMed ID: 25876556
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Chemotherapy-induced neuropathy in multiple myeloma: influence on quality of life and development of a questionnaire to compose common toxicity criteria grading for use in daily clinical practice.
    Beijers AJ; Vreugdenhil G; Oerlemans S; Eurelings M; Minnema MC; Eeltink CM; van de Poll-Franse LV; Mols F
    Support Care Cancer; 2016 Jun; 24(6):2411-20. PubMed ID: 26634561
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Chemotherapy-induced peripheral neuropathy and its impact on health-related quality of life among ovarian cancer survivors: results from the population-based PROFILES registry.
    Ezendam NP; Pijlman B; Bhugwandass C; Pruijt JF; Mols F; Vos MC; Pijnenborg JM; van de Poll-Franse LV
    Gynecol Oncol; 2014 Dec; 135(3):510-7. PubMed ID: 25281491
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Chemotherapy-induced peripheral neuropathy in newly diagnosed breast cancer survivors treated with taxane: a prospective longitudinal study.
    Wang YJ; Chan YN; Jheng YW; Wu CJ; Lin MW; Tseng LM; Tsai YF; Liu LC
    Support Care Cancer; 2021 Jun; 29(6):2959-2971. PubMed ID: 33025227
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Association of Taxane Type With Patient-Reported Chemotherapy-Induced Peripheral Neuropathy Among Patients With Breast Cancer.
    Mo H; Yan X; Zhao F; Teng Y; Sun X; Lv Z; Cao M; Zhao J; Song G; Pan B; Li H; Zhai J; Xu B; Ma F
    JAMA Netw Open; 2022 Nov; 5(11):e2239788. PubMed ID: 36322088
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Patient-Reported Outcome Measures in Chemotherapy-Induced Peripheral Neurotoxicity: Defining Minimal and Clinically Important Changes.
    Li T; Timmins HC; Trinh T; Mizrahi D; Harrison M; Horvath LG; Grimison P; Friedlander M; Kiernan MC; King MT; Rutherford C; Goldstein D; Park SB
    J Natl Compr Canc Netw; 2023 Feb; 21(2):125-132.e3. PubMed ID: 36791763
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Age-related differences in patient-reported and objective measures of chemotherapy-induced peripheral neuropathy among cancer survivors.
    Wong ML; Cooper BA; Paul SM; Abrams G; Topp K; Kober KM; Chesney MA; Mazor M; Schumacher MA; Conley YP; Levine JD; Miaskowski C
    Support Care Cancer; 2019 Oct; 27(10):3905-3912. PubMed ID: 30770977
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Longitudinal validation and comparison of the Chinese version of the European Organization for Research and Treatment of Cancer Quality of Life-Chemotherapy-Induced Peripheral Neuropathy Questionnaire (EORTC QLQ-CIPN20) and the Functional Assessment of Cancer-Gynecologic Oncology Group-Neurotoxicity subscale (FACT/GOG-Ntx).
    Cheng HL; Molassiotis A
    Asia Pac J Clin Oncol; 2019 Feb; 15(1):56-62. PubMed ID: 29873180
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of exercise on chemotherapy-induced peripheral neuropathy in survivors with post-treatment primary breast cancer.
    Saint K; Nemirovsky D; Lessing A; Chen Y; Yang M; Underwood WP; Galantino ML; Jones LW; Bao T
    Breast Cancer Res Treat; 2024 Aug; 206(3):667-675. PubMed ID: 38713289
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Reference data of the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-CIPN20 Questionnaire in the general Dutch population.
    Mols F; van de Poll-Franse LV; Vreugdenhil G; Beijers AJ; Kieffer JM; Aaronson NK; Husson O
    Eur J Cancer; 2016 Dec; 69():28-38. PubMed ID: 27814471
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Chemotherapy-induced peripheral neuropathy in the detroit research on cancer survivors (ROCS) cohort.
    Sreeram K; Seaton R; Greenwald MK; Kamgar M; Assad H; Baird T; Schwartz AG; Ruterbusch J; Simon MS
    Cancer Causes Control; 2023 May; 34(5):459-468. PubMed ID: 36934365
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evidence of slow and variable choice-stepping reaction time in cancer survivors with chemotherapy-induced peripheral neuropathy.
    Menant JC; Goldstein D; Au K; Trinh T; van Schooten KS; McCrary JM; Harris CA; Forster BC; Park SB
    Gait Posture; 2021 Sep; 89():178-185. PubMed ID: 34320441
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Health-related quality of life in early breast cancer.
    Groenvold M
    Dan Med Bull; 2010 Sep; 57(9):B4184. PubMed ID: 20816024
    [TBL] [Abstract][Full Text] [Related]  

  • 38. IMPACT OF CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY ON THE QUALITY OF LIFE IN CANCER PATIENTS.
    Novak M; Miličević J; Bišof V
    Acta Clin Croat; 2022 Mar; 61(1):52-61. PubMed ID: 36530966
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Taxane-Induced Peripheral Neuropathy: Objective and Subjective Comparison Between Paclitaxel and Docetaxel in Patients With Breast Cancer.
    Chan YN; Jheng YW; Wang PJ; Chen CY; Lin MW; Wang YJ
    Clin J Oncol Nurs; 2019 Oct; 23(5):494-501. PubMed ID: 31538967
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Assessing gait, balance, and muscle strength among breast cancer survivors with chemotherapy-induced peripheral neuropathy (CIPN): study protocol for a randomized controlled clinical trial.
    Teran-Wodzinski P; Haladay D; Vu T; Ji M; Coury J; Adams A; Schwab L; Visovsky C
    Trials; 2022 Apr; 23(1):363. PubMed ID: 35477489
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.